Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Suredx LLC currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit. The prosecution for this portfolio is currently focused on a single technical review channel. For a practitioner, this concentration means that the outcome of the entire pending portfolio rests on a single examiner's interpretation of the prior art and patentability requirements in the biotechnology field.
LEITH, NANCY J is the busiest examiner, overseeing 1 pending office action. The alignment of 1 distinct examiner with 1 distinct art unit indicates a concentrated effort within the biotechnology and pharmaceutical sector. Practitioners should focus on the specific examination style of this individual, as there are no other examiners currently providing feedback on the company's applications. This centralized review process simplifies administrative tracking but increases the strategic importance of every interaction with the assigned examiner, particularly regarding pharmaceutical claim breadth.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEITH, NANCY J | 1 | 74.7% | +44.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18467085 | ANTIBODY AND DNA OLIGO CONJUGATES AND THEIR APPLICATION IN ELISA-PCR TESTS | LEITH, NANCY J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18467085 | ANTIBODY AND DNA OLIGO CONJUGATES AND THEIR APPLICATION IN ELISA-PCR TESTS | LEITH, NANCY J | — |
| Art Unit | Apps |
|---|---|
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18467085 | ANTIBODY AND DNA OLIGO CONJUGATES AND THEIR APPLICATION IN ELISA-PCR TESTS | LEITH, NANCY J | 1636 | §102§103§112Other | Final Rejection | — | Pending | Sep 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSuredx LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Nancy J Leith has the most, with 1 of Suredx LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
